Item 7.01 Regulation FD.

On January 10, 2023, Elanco Animal Health Incorporated (the "Company") will present at the 41st Annual J.P. Morgan Healthcare Conference (the "JPM Conference"). A copy of the Company's presentation is furnished as Exhibit 99.1.

In the presentation, the Company notes that in the fourth quarter of 2022 it initiated a submission to the U.S. Food and Drug Administration for its JAK inhibitor.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

Item 9.01 Financial Statements and Exhibits.






(d) Exhibits



Exhibit No.                                Description
  99.1          Investor Presentation of Elanco Animal Health Incorporated at the
              JPM Conference.
104.1         Cover Page Interactive Data File (embedded within the Inline XBRL
              document).

© Edgar Online, source Glimpses